Traditional Chinese medicine composition for treating children allergic rhinitis and children adenoid hypertrophy and application thereof

Through traditional Chinese medicine compositions composed of honeysuckle and other drugs, it can effectively improve symptoms and prevent recurrence for children with allergic rhinitis and adenoid hypertrophy, and solve the problems of high odor and poor effect in existing treatment methods, and has better safety and operability.

CN118987112AActive Publication Date: 2024-11-22SHANGHAI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411059277.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-03
Publication Date
2024-11-22
Estimated Expiration
2044-08-03

AI Technical Summary

Technical Problem

The existing traditional Chinese medicine composition for treating allergic rhinitis and adenoid hypertrophy in children has problems such as excessive medicinal odor, difficult material, expensive price, and insufficient treatment effect. It lacks a significant effect, few medicinal odors, high operability, safe and effective Chinese medicine composition.

Method used

Provide a traditional Chinese medicine composition composed of honeysuckle, fritillaria, forsythia, oyster, burdock, magnolia, mint and astragalus. By eliminating evil, invigorating qi and strengthening the surface, it targets allergic rhinitis and adenoid hypertrophy in children. For treatment, use tablets, capsules, granules or oral liquids in the form of treatment, and take them in batches in the morning and evening.

Benefits of technology

The traditional Chinese medicine composition effectively improves the symptoms of allergic rhinitis and adenoid hypertrophy in children, reduces the size of adenoids, reduces the risk of recurrence, improves the quality of life of children, and shows good safety and clinical efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987112A_ABST
    Figure CN118987112A_ABST
Patent Text Reader

Abstract

The invention relates to a traditional Chinese medicine composition for treating children allergic rhinitis and children adenoid hypertrophy. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7-11 parts of honeysuckle, 7-11 parts of thunberg fritillary bulb, 7-11 parts of fructus forsythiae, 13-17 parts of oyster, 7-11 parts of burdock, 4-8 parts of biond magnolia flower, 4-8 parts of mint, 7-11 parts of rhizoma atractylodis and 7-11 parts of astragalus membranaceus. The invention further provides application of the traditional Chinese medicine composition. After intervention, the traditional Chinese medicine has a good clinical curative effect on a child patient suffering from adenoid hypertrophy, the A / N ratio of adenoid of the child patient can be reduced, clinical symptoms of the child patient can be relieved, the life quality of the child patient can be improved, and the traditional Chinese medicine has good safety. Research results show that after traditional Chinese medicine intervention, the traditional Chinese medicine has a good clinical curative effect on children allergic rhinitis, the EOS count of peripheral blood of a child patient can be reduced, clinical symptoms of the child patient can be relieved, and the life quality of the child patient can be improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating children's allergic rhinitis and children's adenoids hypertrophy and an application thereof. Background Art

[0002] Adenoids are a group of lymphoid tissues located at the junction of the top and back walls of the nasopharynx, between the pharyngeal recesses on both sides, also known as pharyngeal tonsils and adenoids. Adenoid hypertrophy is not clearly recorded in ancient Chinese medical books, and is currently often classified as "nasal congestion", "phlegm nodules", "snoring", "nest cysts", "neck pain", etc. Adenoid hypertrophy (AH) refers to a disease in which the adenoids undergo pathological hyperplasia due to repeated inflammatory stimulation, causing a series of symptoms. Its main symptoms include: snoring during sleep, mouth breathing, nasal congestion, and severe cases may be seen holding breath and apnea during sleep. Long-term hypoxia causes children to have poor spirits, learning difficulties, slow growth and development, and "adenoid face". Obstructive sleep apnea hypopnea syndrome (OSAHS) refers to a series of pathological and physiological changes caused by frequent partial or complete upper airway obstruction during sleep, disrupting the normal ventilation and sleep structure of children. Adenoid hypertrophy is one of the most common causes of OSAHS in children.

[0003] Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mediated primarily by immunoglobulin E (IgE) after atopic individuals are exposed to allergens (allergens).

[0004] Chinese patent document CN104398711A discloses a Chinese medicine composition for treating allergic rhinitis in children, wherein the active ingredients contained in the composition are prepared by the following weight proportions of raw materials: 2-4 parts of honey-roasted ephedra, 2-4 parts of cassia twig, 3-9 parts of magnolia, 3-9 parts of xanthium sibiricum, 3-9 parts of schisandra chinensis, 3-9 parts of ebony, 3-9 parts of gall bladder arisaema, and 5-15 parts of cynanchum chinense. The invention also discloses a preparation method and application of the above-mentioned medicine. The Chinese medicine composition of the invention has the effects of promoting lung function, benefiting the orifices, eliminating wind and resolving phlegm, and clinical studies have confirmed that the composition has a significant therapeutic effect on treating allergic rhinitis in children, and can not only improve the symptoms of children with allergic rhinitis, but also improve the atopic constitution of children to a certain extent, and is an ideal medicine for treating allergic rhinitis in children.

[0005] Chinese patent document CN105030972A discloses a Chinese medicine preparation for treating adenoids hypertrophy in children and a preparation method thereof. The Chinese medicine preparation is prepared from the following drugs: Astragalus, Radix Pseudostellariae, Rhizoma Chuanxiong, Rhizoma Corydalis, Kelp, Fructus Forsythiae, Fructus Xanthii, Borneolum, Pericarpium Citri Reticulatae, Platycodon. The Chinese medicine preparation of the present invention has a reasonable formula, is easy to prepare, has significant curative effects of invigorating the spleen and moistening the lungs, promoting qi and activating blood circulation, softening and dispersing nodules, relieving throat pain and resolving phlegm, and is an effective drug for treating adenoids hypertrophy in children, especially adenoids hypertrophy in children of qi and blood stasis type.

[0006] There are many traditional Chinese medicine compositions for treating allergic rhinitis and adenoids hypertrophy in children, but they all have more or less disadvantages, such as too many medicinal flavors, difficult to obtain materials, expensive prices, unclear efficacy, poor therapeutic effect, etc. Therefore, there is an urgent need for a traditional Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children, which has obvious effects, few medicinal flavors, is practical, highly compliant, safe and effective. Summary of the invention

[0007] The purpose of the present invention is to provide a Chinese medicine composition for treating children's allergic rhinitis and children's adenoids hypertrophy and its application in view of the deficiencies in the prior art.

[0008] In a first aspect, the present invention provides a traditional Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7-11 parts of honeysuckle, 7-11 parts of Fritillaria thunbergii, 7-11 parts of Forsythia suspensa, 13-17 parts of oyster, 7-11 parts of burdock, 4-8 parts of magnolia, 4-8 parts of mint, 7-11 parts of atractylodes, and 7-11 parts of astragalus.

[0009] As a preferred example, the Chinese medicine composition is made of the following raw materials in parts by weight: 8-10 parts of honeysuckle, 8-10 parts of Fritillaria thunbergii, 8-10 parts of forsythia, 14-16 parts of oyster, 8-10 parts of burdock, 5-7 parts of magnolia, 5-7 parts of mint, 8-10 parts of atractylodes, and 8-10 parts of astragalus.

[0010] As another preferred example, the Chinese medicine composition is made of the following raw materials in parts by weight: 9 parts of honeysuckle, 9 parts of Fritillaria thunbergii, 9 parts of Forsythia suspensa, 15 parts of oyster, 9 parts of Burdock fruit, 6 parts of Magnolia officinalis, 6 parts of mint, 9 parts of Atractylodes macrocephala, and 9 parts of Astragalus.

[0011] As another preferred example, the Chinese medicine composition is in the form of tablets, capsules, granules, oral liquids or syrups.

[0012] In a second aspect, the present invention provides the use of a traditional Chinese medicine composition in the preparation of a medicine for treating allergic rhinitis and adenoids hypertrophy in children.

[0013] This Chinese medicine formula is mainly used for allergic rhinitis and adenoids hypertrophy in children. It can effectively improve symptoms such as itchy nose, sneezing, nasal congestion, runny nose, etc. in children with rhinitis, and improve symptoms such as snoring, mouth breathing, nasal congestion, etc. in children with adenoids hypertrophy, and reduce the volume of adenoids and reduce the risk of recurrence of adenoids hypertrophy.

[0014] Usage: 9 parts of honeysuckle, 9 parts of Fritillaria thunbergii, 9 parts of forsythia, 15 parts of oyster, 9 parts of burdock, 6 parts of magnolia, 6 parts of mint, 9 parts of atractylodes, 9 parts of astragalus, take with boiling water, a total of 100 ml, take twice a day, morning and evening.

[0015] The advantages of the present invention are:

[0016] The key to the recurrence and protracted cure of allergic rhinitis and adenoids hypertrophy is the invasion of wind and phlegm. Pathological products are mixed in the whole course of the disease. The treatment should focus on attacking the evil and replenishing qi and strengthening the exterior. Clinically, honeysuckle, Fritillaria thunbergii, oyster, forsythia, burdock, magnolia, mint, atractylodes, and astragalus are used to treat allergic rhinitis and adenoids hypertrophy.

[0017] The onset of the disease caused by exogenous pathogens is rapid and the course of the disease is short. The course of the disease may follow the six meridians, or follow the rules of the transformation of the Wei Qi, Ying Qi, and San Jiao. In addition, the physiological and pathological characteristics of children's organs are delicate and the transformation is rapid, so it is particularly important to eliminate the pathogens. The pathogens are not always there, and if they exist, they should be eliminated. This is as Zhang Congzheng said, "The disease is caused by the pathogens, and attacking the pathogens will cause the disease." As for eliminating the pathogens, one of the principles is to take advantage of the situation and give the pathogens a way out. In other words, it is necessary to choose the appropriate method and the nearest way according to the origin, nature, location, severity, etc. of the pathogens, such as "Suwen·Yin Yang Ying Xiang Da Lun" says: "Because it is light, it should be lifted,...". Allergic rhinitis and adenoids hypertrophy in children are both upper respiratory tract diseases. The nose is the orifice of the lungs, and the throat is the gateway to the lung defense. This prescription uses ingredients with light texture and taste to attack the evil spirits in the upper part of the body, and strengthens the barrier function of the nasopharynx by removing the evil spirits. It can prevent the disease from changing and prevent the disease before it occurs. Therefore, while improving the symptoms of children by removing the evil spirits, it also prevents the recurrence of the disease. It combines prevention with treatment, and achieves the effect of preventing and treating allergic rhinitis and adenoids hypertrophy in children from both the "symptoms" and the "root cause".

[0018] This prescription is derived from the academic thoughts of Jia Liujin, a famous Chinese medicine doctor in China, and is modified from Yinqiao Powder and Xiaoluo Pills. Jia is good at using Yinqiao Powder to treat recurrent respiratory tract infections in children. He believes that children with recurrent respiratory tract infections are mostly in a state of mixed deficiency and excess, and the main cause is evil. Yinqiao Powder is effective in expelling evil. The dosage is light and the taste is light, so that the evil qi cannot invade the middle jiao and comes out from the upper jiao; short-term decoction and frequent medication allow the drug to continue to act on the upper jiao, so that the disease will not be prolonged and transferred to the middle and lower jiao. For the upper jiao of the human body, expelling evil from the body belongs to preventing changes after the disease occurs, and for the middle jiao, "first calming the place that has not been affected by evil" belongs to prevention before the disease occurs. It can treat and prevent at the same time, killing two birds with one stone.

[0019] In this prescription, honeysuckle is light and sweet, cold in nature, dispersing wind-heat and dispersing external pathogens; Fritillaria thunbergii is bitter and cold, and enters the lung and heart meridians, and is pungent and dispersing, dissolving phlegm, softening and dispersing nodules. The two are the main medicines; Forsythia suspensa is light and clear, and is good at going up to the upper part of the body, helping honeysuckle dispersing wind and dispersing evil, and oysters with their salty nature help Fritillaria thunbergii dispersing phlegm and softening nodules, and are the assistant medicines; Atractylodes lancea is used to strengthen the spleen and resolve phlegm, and Astragalus membranaceus is used to invigorate qi and consolidate the exterior; Burdock seeds clear the throat, and Magnolia officinalis and mint clear the nasal passages. The combination of these medicines can achieve the purpose of dispelling evil qi, regulating lung qi, and removing wind and phlegm, and the pungent and cool wind and heat are used to dispel evil, and resolve phlegm, soften and disperse nodules to open the orifices.

[0020] The Chinese medicine intervention of the present invention has a good clinical effect on children with adenoid hypertrophy, can reduce the A / N ratio of the adenoids of the children, relieve the clinical symptoms of the children, improve the quality of life of the children, and has good safety. The research results of the present invention show that the Chinese medicine intervention has a good clinical effect on children with allergic rhinitis, can reduce the peripheral blood EOS count of the children, relieve the clinical symptoms of the children, and improve the quality of life of the children. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Comparison of peripheral blood EOS counts between the two groups before and after treatment;

[0022] Note: Compared with before treatment, △ P<0.05, △△ P<0.001; compared with the control group, * P<0.05, ** P<0.001. DETAILED DESCRIPTION

[0023] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0024] Example 1 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (I)

[0025] 9 parts of honeysuckle, 9 parts of fritillaria thunbergii, 9 parts of forsythia suspensa, 15 parts of oysters, 9 parts of arctium fruits, 6 parts of magnolia, 6 parts of peppermint, 9 parts of atractylodes, and 9 parts of astragalus.

[0026] Example 2 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (II)

[0027] 9 parts of honeysuckle, 7 parts of fritillaria thunbergii, 11 parts of forsythia suspensa, 14 parts of oysters, 10 parts of arctium fruits, 6 parts of magnolia, 4 parts of peppermint, 11 parts of atractylodes, and 8 parts of astragalus.

[0028] Example 3 Chinese medicinal composition for treating allergic rhinitis and adenoids hypertrophy in children (III)

[0029] 7 parts of honeysuckle, 11 parts of fritillaria thunbergii, 8 parts of forsythia suspensa, 16 parts of oysters, 9 parts of arctium fruits, 4 parts of magnolia, 8 parts of peppermint, 8 parts of atractylodes, and 10 parts of astragalus.

[0030] Example 4 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (IV)

[0031] 11 parts of honeysuckle, 8 parts of thunbergia thunbergii, 10 parts of forsythia suspensa, 15 parts of oysters, 7 parts of arctium fruits, 8 parts of magnolia flowers, 5 parts of peppermint, 10 parts of atractylodes, and 9 parts of astragalus.

[0032] Example 5 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (V)

[0033] 8 parts of honeysuckle, 10 parts of fritillaria thunbergii, 9 parts of forsythia suspensa, 13 parts of oysters, 11 parts of arctium fruits, 5 parts of magnolia, 7 parts of peppermint, 9 parts of atractylodes, and 7 parts of astragalus.

[0034] Example 6 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (VI)

[0035] 10 parts of honeysuckle, 9 parts of fritillaria thunbergii, 7 parts of forsythia suspensa, 17 parts of oysters, 8 parts of arctium fruits, 7 parts of magnolia flowers, 6 parts of peppermint, 7 parts of atractylodes, and 11 parts of astragalus.

[0036] Example 7 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (VII)

[0037] 9 parts of honeysuckle, 11 parts of thunbergia thunbergii, 8 parts of forsythia suspensa, 16 parts of oysters, 9 parts of arctium fruits, 4 parts of magnolia, 8 parts of peppermint, 8 parts of atractylodes, and 10 parts of astragalus.

[0038] Example 8 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (VIII)

[0039] 7 parts of honeysuckle, 8 parts of thunbergia thunbergii, 10 parts of forsythia, 15 parts of oysters, 7 parts of arctium fruits, 8 parts of magnolia, 5 parts of peppermint, 10 parts of atractylodes, and 9 parts of astragalus.

[0040] Example 9 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (IX)

[0041] 11 parts of honeysuckle, 10 parts of fritillaria thunbergii, 9 parts of forsythia suspensa, 13 parts of oysters, 11 parts of arctium fruits, 5 parts of magnolia, 7 parts of peppermint, 9 parts of atractylodes, and 7 parts of astragalus.

[0042] Example 10 Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children (ten)

[0043] 8 parts of honeysuckle, 9 parts of thunbergia thunbergii, 7 parts of forsythia, 17 parts of oyster, 8 parts of arctium, 7 parts of magnolia, 6 parts of peppermint, 7 parts of atractylodes, and 11 parts of astragalus.

[0044] Example 11 Chinese medicinal composition for treating allergic rhinitis and adenoids hypertrophy in children (XI)

[0045] 10 parts of honeysuckle, 7 parts of thunbergia thunbergii, 11 parts of forsythia suspensa, 14 parts of oysters, 10 parts of arctium fruits, 6 parts of magnolia, 4 parts of peppermint, 11 parts of atractylodes, and 8 parts of astragalus.

[0046] Example 12 Clinical Trial on Treatment of Adenoid Hypertrophy in Children

[0047] 1. Research content and methods

[0048] 1 General Information

[0049] Case source: The child went to Shanghai Hospital of Traditional Chinese Medicine for treatment from May 2023 to March 2024 and was diagnosed with adenoids hypertrophy.

[0050] 2 Case selection

[0051] 2.1 Western medicine diagnostic criteria

[0052] The diagnostic criteria for AH were formulated with reference to Zhu Futang's Practical Pediatrics (8th Edition) Volume 2 (2015) and the "Expert Consensus on the Diagnosis and Treatment of Sleep Disordered Breathing Caused by Adenoid Hypertrophy in Children" compiled by the Children's Sleep Disordered Breathing Working Committee of the Sleep Medicine Technical Standard Review Committee of the World Federation of Chinese Medicine Societies:

[0053] Clinical manifestations: intermittent or recurrent snoring during sleep, open mouth breathing, nasal congestion, even apnea, waking up at night due to suffocation; complications may be accompanied by hearing loss, increased nasal secretions, cough, headache, olfactory impairment, etc. Some children may have a typical adenoid face, such as elongated jaw, high arched palate, protruding upper incisors, thick lips, etc.

[0054] Auxiliary examinations: (1) Lateral X-ray of the nasopharynx: Thickening of the soft tissue of the posterior wall of the nasopharynx, narrowing of the airway due to compression, and adenoids index (A / N ratio) ≥ 0.71. (2) Axial CT scan of the nasopharynx: Narrowing of the nasopharyngeal air cavity and thickening of the posterior wall soft tissue can be seen. Symptoms such as sinus consolidation and otitis media may be present. The A / N ratio measured by sagittal reconstruction images is > 0.70. (3) MRI of the nasopharynx: Adenoids are located on the posterior wall of the nasopharynx, appearing as space-occupying masses, with local increased thickness and varying degrees of narrowing of the pharyngeal cavity. The A / N ratio measured by midsagittal images is ≥ 0.70. (4) Nasal endoscopy or nasopharyngoscopy: On the posterior wall of the nasopharynx, lobed lymphoid tissue with longitudinal fissures on the surface can be seen to be prominent, exceeding more than 1 / 2 of the nasopharyngeal cavity.

[0055] Adenoids hypertrophy can be diagnosed if any auxiliary examination is supported and accompanied by relevant clinical symptoms.

[0056] 2.2 Inclusion criteria

[0057] (1) Meet the diagnostic criteria for adenoids hypertrophy and TCM syndrome differentiation criteria;

[0058] (2) Children aged 3-12 years were enrolled, regardless of gender;

[0059] (3) Those whose legal guardians have signed an informed consent form and who are able to cooperate with treatment.

[0060] 2.3 Exclusion criteria

[0061] (1) Not meeting the inclusion criteria

[0062] (2) Those who have received other medications or surgical treatments in the past 2 weeks or have participated in other related drug clinical trials.

[0063] (3) Those with severe nasal septum deviation, or those who have difficulty breathing due to obesity, nasal polyps, upper airway neuromuscular tension, laryngeal and tracheal diseases, etc.;

[0064] (4) Patients with severe liver or kidney diseases, cardiovascular diseases, endocrine diseases, blood system diseases, or nervous system diseases;

[0065] (5) Those who are known to be allergic to the drugs in this prescription;

[0066] 2.4 Criteria for case exclusion, dropout and trial termination

[0067] Exclusion: Misdiagnosed cases were included. Subjects were excluded when they did not take the prescribed medication, or when the data records were incomplete or when they had other symptoms.

[0068] Dropout: All subjects included in the clinical study who withdraw on their own or fail to complete the treatment and observation period of the study regimen are considered to have dropped out.

[0069] Termination of the trial: When researchers discover safety issues or major errors in the protocol, the trial should be terminated.

[0070] 3. Treatment options

[0071] Chinese medicine group (treatment group): honeysuckle 9g, Fritillaria thunbergii 9g, forsythia suspensa 9g, oyster 15g, burdock fruit 9g, magnolia 6g, mint 6g, atractylodes 9g, and astragalus 9g.

[0072] Usage: The above Chinese medicine granules are provided by Sichuan New Green Pharmaceutical Co., Ltd. Take 1 dose per day, dissolve in warm water, and take in the morning and evening. Each course of treatment lasts 4 weeks, for a total of 3 courses.

[0073] Western medicine group (control group): Montelukast sodium tablets for oral administration: 3-6 years old, 4 mg each time, once every night; 6+-14 years old, 5 mg each time, once every night. Pingqi (Montelukast Sodium Tablets), Lunan Beite Pharmaceutical Co., Ltd., product approval number: National Medicine Standard H20083372. Each course of treatment lasts for 4 weeks, for a total of 3 courses.

[0074] 4. Observation indicators

[0075] 4.1 General information: age, gender, height, weight, course of disease, etc.

[0076] 4.2 Efficacy indicators:

[0077] (1) Adenoid volume integral scoring criteria:

[0078] Table 1A / N quantitative scoring criteria

[0079]

[0080]

[0081] (2) Quantitative scoring standards for TCM clinical syndromes

[0082] Table 2 Symptom grading and quantification table

[0083]

[0084] (3) Quality of life assessment (OSA-18)

[0085] The children's obstructive sleep apnea disease-specific quality of life questionnaire (OSA-18) was used for scoring, which includes 5 aspects, including sleep disorders, physical symptoms, bad mood, daytime function and the degree of impact on guardians, with 18 items. The above questionnaire was used for scoring.

[0086] 4.3 Safety indicators: routine blood test, high-sensitivity C-reactive protein, routine urine test, liver and kidney function.

[0087] 4.4 Observation time

[0088] 4.4.1 General physical examination items, diagnostic indicators and pre-treatment examination

[0089] 4.4.2 Children’s A / N ratio, TCM syndrome scale, and OSA-18 scale: Day 0 and month 3 were selected as observation time points during the treatment period.

[0090] 5. Efficacy evaluation criteria

[0091] 5.1 Quantitative standard for the improvement of nasopharyngeal lateral radiographs

[0092] Because the degree of adenoid hypertrophy in children before treatment was different, only counting the degree of adenoid hypertrophy could not fully reflect the efficacy of the corresponding treatment plan. Therefore, this study added the objective indicator of lateral nasopharyngeal radiograph A / N ratio, and developed a grading and quantitative table for the degree of improvement of lateral nasopharyngeal radiographs based on the nimodipine method. The degree of improvement of the A / N ratio of lateral nasopharyngeal radiographs was used to more objectively determine the efficacy.

[0093]

[0094] Note: This calculation formula is based on the nimodipine method. Since a lateral nasopharyngeal radiograph with a value of 0≤A / N≤0.6 can be considered clinically cured, the ratio of the difference in the A / N ratio before and after treatment to the excess of the A / N ratio before treatment is used as the standard, i.e., the calculation formula (degree of improvement)

[10] = [(ratio before treatment - ratio after treatment) ÷ (ratio before treatment - 0.6)] × 100%.

[0095] 5.2 Criteria for judging the efficacy of TCM syndromes

[0096] Refer to the "Guidelines for Clinical Research of New Chinese Medicines (Trial)" formulated by the Ministry of Health in 2002 and the "Technical Requirements for Research of New Chinese Medicines" formulated by the State Administration of Traditional Chinese Medicine in 2000.

[0097]

[0098] Note: Calculation formula (nimodipine method) = [(pre-treatment score - post-treatment score) ÷ pre-treatment score] × 100%.

[0099] 5.3 Quality of life criteria

[0100] Scale filling: Professional physicians help the guardians of children to complete the OSA-18 questionnaire and calculate the relevant scores for each subject (child) included in the study:

[0101] Total score: the sum of the scores of each item in the OSA-18 questionnaire. The score ranges from 18 to 126 points. This score is used to evaluate the impact of snoring on the quality of life of children: ① Mild impact: total score is 59 points or below; ② Moderate impact: total score is between 60 and 80 points; ③ Severe impact: total score is 81 points or above.

[0102] Change value: It is the difference between the average score before treatment (the total score of the OSA-18 questionnaire before treatment divided by 18 or the total score of each dimension divided by the number of items included in the dimension) and the average score after treatment. The change in the child's quality of life before and after treatment can be measured based on the change value of the OSA-18 questionnaire scoring standard.

[0103] Efficacy evaluation: The change value range of the OSA-18 questionnaire is: -7 points to 7 points, negative points indicate worsening of quality of life, and positive points indicate improvement of quality of life. The specific evaluation criteria are: ① Slight improvement: change value <0.50; ② Mild improvement: 0.50≤change value <1.00; ③ Moderate improvement: 1.00≤change value <1.50; ④ Significant improvement: change value ≥1.50.

[0104] 6 Statistical methods

[0105] This study used SPSS27.0 statistical analysis software for statistical analysis. The chi-square test was used for count data, and the measurement data were expressed as mean ± standard deviation. The t-test was used for data that met the normal distribution and homogeneity of variance, and the non-parametric test was used for data that did not meet the normal distribution. The rank sum test was used for rank data. P < 0.05 was considered statistically significant, and P < 0.01 was considered statistically significant.

[0106] II. Research Results

[0107] 1 Baseline information

[0108] A total of 66 children who met the inclusion criteria and visited the Department of Pediatrics of Shanghai Hospital of Traditional Chinese Medicine from May 2023 to March 2024 were selected. They were divided into a control group and a treatment group using a random number table. A total of 33 children were included in the control group, including 22 males and 11 females, with an average age of 6.91±2.19 and a BMI of 20.99±2.79kg / m 2 A total of 33 patients were included in the treatment group, including 18 males and 15 females, with an average age of 7.27±2.11 years and a BMI of 20.38±2.43kg / m 2 There were no significant differences in gender, age, and BMI between the two groups (all P>0.05), and the two groups were comparable. The children and their guardians signed informed consent forms, and the research content was reviewed and approved by the hospital ethics committee (approval number: 2024SHL-KY-59-02).

[0109] Table 1 Comparison of gender between the two groups

[0110]

[0111] Note: There was no statistical difference in gender between the two groups, P=0.314>0.05, so the two groups were comparable.

[0112] Table 2 Comparison of age between the two groups

[0113]

[0114] Note: There was no statistical difference in the ages of the two groups of children (P=0.914>0.05), so they were comparable.

[0115] Table 3 Comparison of BMI between the two groups of children

[0116]

[0117] Note: Comparison between the two groups of children showed that BMIP=0.467>0.05, with no statistical difference and comparable.

[0118] 2 Comparison of adenoids hypertrophy volume scores before and after treatment

[0119] Before treatment, there was no significant difference in the degree of adenoid hypertrophy between the two groups (P>0.05), which was comparable. After 12 weeks of treatment, both groups showed improvement compared with before treatment (P<0.001), and the treatment group was better than the control group (P<0.001). See Table 4.

[0120] Table 4 Comparison of adenoids hypertrophy volume scores between the two groups of children ( point)

[0121]

[0122] 3 Comparison of TCM syndrome scores before and after treatment

[0123] There was no statistical difference in the scores of the main TCM syndromes of the two groups of children before treatment (P>0.05), which was comparable. There was no statistical difference in the scores of the minor TCM syndromes of the two groups of children before treatment (P>0.05), which was comparable. There was no statistical difference in the total scores of TCM syndromes of the two groups of children before treatment (P>0.05), which was comparable. After 12 weeks of treatment, the scores of TCM syndromes of the two groups of children were significantly improved compared with those before treatment, and the difference was statistically significant (P<0.001), indicating that all symptoms of the two groups were improved after 12 weeks of treatment compared with those before treatment; and the therapeutic effect of the treatment group was better than that of the control group (P<0.001). See Table 5 and Table 6.

[0124] Table 5 Comparison of the scores of major / minor TCM syndromes between the two groups of children (points)

[0125]

[0126] Note: *P<0.05

[0127] Table 6 Comparison of total scores of TCM syndromes between the two groups of children (points)

[0128]

[0129] 4 Comparison of OSA-18 scores between the two groups

[0130] There was no significant difference in OSA-18 scores between the two groups before treatment (P>0.05), which was comparable. After 12 weeks of treatment, both groups improved compared with before treatment (P<0.001), and the treatment group was better than the control group (P<0.001). See Table 7.

[0131] Table 7 Comparison of OSA-18 scores between the two groups of children (points)

[0132]

[0133] 5 Comparison of clinical efficacy

[0134] After 12 weeks of treatment, the total effective rate of the control group was 60.60%, and the effective rate of the treatment group was 87.88%, and the difference in efficacy between the two groups was statistically significant (P < 0.05). See Table 8.

[0135] Table 8 Comparison of clinical efficacy between the two groups [n (%)]

[0136]

[0137] 6 Adverse Reactions

[0138] At enrollment, no abnormal liver and kidney function indicators (ALT, AST, BUN, Cr) were found in the two groups of children. After 3 months of treatment, no abnormal liver and kidney function indicators (ALT, AST, BUN, Cr) were found in the two groups of children.

[0139] 3. Conclusion

[0140] The research results of the present invention show that Chinese medicine intervention has a good clinical effect on children with adenoids hypertrophy, can reduce the A / N ratio of the children's adenoids, relieve the children's clinical symptoms, improve the children's quality of life, and has good safety.

[0141] Example 13 Clinical trial on the treatment of allergic rhinitis in children

[0142] 1. Research content and methods

[0143] 1Case Source

[0144] All cases were from children with allergic rhinitis in the outpatient department of the Shanghai University of Traditional Chinese Medicine Affiliated Hospital of Traditional Chinese Medicine from January 2022 to March 2023. Children who met the inclusion criteria were collected as the research subjects of this study. All cases met the ethical requirements, and the children and parents were fully informed before enrollment and signed informed consent. This study complies with the ethical requirements of the Shanghai University of Traditional Chinese Medicine Affiliated Hospital of Traditional Chinese Medicine (Ethics Approval No.: 2022SHL-KY-55-01)

[0145] 2 Case selection

[0146] 2.1 Western medicine diagnostic criteria

[0147] According to the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis in Children" issued by the Rhinology Group of the Editorial Committee of the Chinese Journal of Otolaryngology and Head and Neck Surgery in 2011, the Rhinology Group and Pediatric Group of the Otolaryngology and Head and Neck Surgery Branch of the Chinese Medical Association, the specific diagnostic criteria are as follows:

[0148] (1) Have a typical history of allergies, such as a history of eczema, a family history of allergic diseases, etc.

[0149] (2) Clinical symptoms mainly manifest as upper respiratory tract symptoms: including nasal congestion, runny nose, nasal itching, paroxysmal sneezing and other local symptoms appearing for more than 2 items (including 2 items), and the symptoms last or accumulate for more than 1 hour per day.

[0150] (3) Physical signs: pale and swollen bilateral nasal mucosa, edema of the inferior turbinate, clear watery nasal secretions, allergic dark circles under the eyes, Dennie lines, allergic wrinkles, friction marks on the lips, etc.

[0151] (4) Auxiliary examinations: Allergen skin prick test and / or serum allergen-specific IgE assay are positive.

[0152] Excluding typical symptoms such as recurrent nasal congestion, sneezing, runny nose, etc. caused by other diseases, the diagnosis can be made if the typical symptoms, signs, auxiliary examinations and medical history are met.

[0153] 2.2 TCM diagnostic criteria

[0154] Referring to the diagnostic criteria for pediatric allergic rhinitis in the 2016 "Guidelines for Clinical Diagnosis and Treatment of Pediatric Allergic Rhinitis in TCM" and the "Guidelines for Diagnosis and Treatment of Common Pediatric Diseases in TCM" published by the Chinese Association of Traditional Chinese Medicine in 2012, combined with the clinical reality of this disease, the TCM diagnostic criteria are as follows:

[0155] (1) Medical history: The patient has a history of recurrent illness, often with a history or family history of allergic diseases such as infantile eczema and urticaria.

[0156] (2) Clinical manifestations: 2 or more symptoms such as nasal itching, sneezing, runny nose, and nasal congestion, which last or accumulate for more than 1 hour per day. It may be accompanied by eye symptoms such as eye itching and conjunctival congestion.

[0157] (3) Physical signs: Common nasal mucosa is pale, grayish white or light blue, and edematous. In a few cases, the nasal mucosa is congested, the nasal concha is swollen, and there is watery nasal secretion. Children with severe symptoms may develop allergic dark circles and allergic wrinkles.

[0158] (4) Laboratory examination: Blood routine: total white blood cell count is normal, eosinophils may be increased. Nasal secretions may be positive for eosinophils and mast cells. Skin prick test, serum total IgE test, serum specific IgE test, and serological allergen antibody test are all helpful in assisting diagnosis.

[0159] 2.3 Inclusion criteria

[0160] (1) Meet the Western medical diagnostic criteria for allergic rhinitis;

[0161] (2) The diagnosis of pediatric allergic rhinitis is in accordance with the "Guidelines for Clinical Diagnosis and Treatment of Pediatric Allergic Rhinitis in Traditional Chinese Medicine" and the "Guidelines for Diagnosis and Treatment of Common Diseases in Pediatrics in Traditional Chinese Medicine" published by the Chinese Association of Traditional Chinese Medicine in 2012;

[0162] (3) Aged 5 to 11, regardless of gender, and able to cooperate with the treatment;

[0163] (4) Not taking other drugs for rhinitis in the past week and not participating in other clinical studies;

[0164] (5) The patient's parents or other legal guardians provide informed consent;

[0165] 2.4 Exclusion criteria

[0166] (1) Children who do not meet the diagnostic criteria for allergic rhinitis;

[0167] (2) Those who are allergic to the drugs in this study;

[0168] (3) Patients with rhinitis-like symptoms caused by other diseases such as upper respiratory tract infection;

[0169] (4) Children with allergic rhinitis and severe complications, such as abnormal nasal anatomy, severe nasal polyps, chronic sinusitis, etc.;

[0170] (5) Those with serious diseases of other organs, such as heart, liver, kidney, etc.;

[0171] (6) Researchers who are unable to complete this trial due to other reasons;

[0172] (7) Those who are deemed unsuitable to participate in this study by the researcher;

[0173] 2.5 Falling off and rejection criteria

[0174] (1) Those with poor compliance or who actively requested to withdraw from this study were considered dropouts;

[0175] (2) Serious adverse events, such as adverse reactions, are included in the statistics of adverse reactions;

[0176] (3) Patients who dropped out due to ineffectiveness will be included in the efficacy analysis; those who did not persist in 1 / 2 course of treatment will be considered to have dropped out; those who persisted in more than 1 / 2 course of treatment will be included in the efficacy statistics;

[0177] (4) The included cases did not take the prescribed medication, had an insufficient course of treatment, or had incomplete case reports;

[0178] 3 Treatment options

[0179] 3.1 Experimental Grouping

[0180] A total of 94 children with allergic rhinitis were collected from the pediatric outpatient department of Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine. The case numbers were set from 1 to 94 according to the order of visit, and random numbers without repeated numbers were generated using SPSS25.0 software. The random numbers were numbered 1-94 from small to large, and then divided into a control group (No. 1-47) and a treatment group (No. 48-94) according to the sequence from low to high.

[0181] 3.2 Treatment methods

[0182] Treatment group: On the basis of the control group, the following Chinese medicines were used in combination: honeysuckle 9g, Fritillaria thunbergii 9g, forsythia suspensa 9g, oyster 15g, burdock fruit 9g, magnolia 6g, mint 6g, atractylodes 9g, and astragalus 9g. The above Chinese medicine granules were provided by Sichuan New Green Pharmaceutical Company. One dose per day, washed with warm water, taken in the morning and evening. 7 days is one course of treatment, and there are 2 courses in total.

[0183] Control group: mometasone furoate nasal spray (Zhejiang Xianjun Pharmaceutical Co., Ltd., National Medicine Standard H20113481, 50μg×60 presses) was administered nasally, 5-6 years old: 1 press per nostril, once a day; 7-11 years old: 1 press per nostril, once a day. 7 days is one course of treatment, for a total of 2 courses.

[0184] 4 Observation indicators

[0185] 4.1 General Information

[0186] Record the child's general information such as gender, age, height, weight, and allergy history.

[0187] 4.2 Symptoms and signs efficacy observation indicators

[0188] With reference to the "Guidelines for Clinical Diagnosis and Treatment of Pediatric TCM·Allergic Rhinitis in Children" and "Guidelines for Clinical Research of New Chinese Medicines", and combined with the clinical practice of allergic rhinitis, the symptom scoring standard was formulated:

[0189] 1) Scoring criteria for main symptoms and signs:

[0190] Table 9 Scoring criteria for main symptoms and signs

[0191]

[0192] 2) Secondary symptom scoring criteria:

[0193] Table 10 Symptom Scoring Criteria

[0194]

[0195] 4.3 Blood eosinophil count

[0196] The eosinophil counts (EOS) in peripheral blood were detected before and after treatment.

[0197] 5 Clinical efficacy evaluation criteria

[0198] The efficacy evaluation criteria were formulated with reference to the Guiding Principles for Clinical Research of New Chinese Medicines edited by Zheng Xiaoyu in 2002:

[0199] Markedly effective: clinical symptoms and signs are significantly improved, and the symptom score is reduced by ≥70%;

[0200] Effective: clinical symptoms and signs are improved, and the symptom score is reduced by ≥30% and <70%;

[0201] Ineffective: clinical symptoms and signs have no significant improvement, or even worsen, and the symptom score decreases by less than 30%;

[0202] Note: Efficacy index = (total score before treatment - total score after treatment) / total score before treatment × 100%

[0203] 6 Statistical methods

[0204] All data were statistically analyzed using SPSS 25.0 software. The clinical observation data of the two groups of children were expressed as mean ± standard deviation. The median, upper quartile, and lower quartile are expressed as follows. If the measurement data meet the normal distribution and variance homogeneity, the t test and (or) paired t test are used. For the measurement data that do not meet the normal distribution or variance heterogeneity, the Mann-Whitney U test for two independent samples and the Wilcoxon test for two related samples are used for comparison of the rank data. For multiple rates or multiple constituent ratios, the chi-square test is used for comparison. 2 Two-sided test was used with P < 0.05 as the statistically significant difference.

[0205] II. Research Results

[0206] 1 General Data Comparison

[0207] A total of 94 children were included in this study and randomly divided into a control group and a treatment group of 47 cases each. During the study, 5 cases dropped out, including 3 cases in the control group, 1 case of complicated bronchial pneumonia, and 2 cases of parents' failure to cooperate in the later stage; 2 cases in the treatment group dropped out, 1 case of complicated acute respiratory tract infection, and 1 case of parents taking other drugs on their own. A total of 89 children completed the experiment. The general information, gender composition, course of disease, and pulmonary ventilation function of the two groups of children are shown in Tables 11 and 12.

[0208] Table 11 Comparison of baseline data between the two groups

[0209]

[0210] Table 12 Comparison of baseline data between the two groups

[0211]

[0212]

[0213] As shown in the table above, the control group included 44 cases (male: female = 33:11), with an average age of 7.39 ± 1.81 years, an average height of 130.57 ± 11.34 cm, an average weight of 29.75 ± 9.06 kg, and an average course of disease of 1.28 ± 1.09 years; the treatment group included 45 cases (male: female = 29:16), with an average age of 7.20 ± 2.10 years, an average height of 125.91 ± 12.64 cm, an average weight of 26.42 ± 10.27 kg, and an average course of disease of 1.21 ± 1.08 years. The distribution of pulmonary ventilation function in both groups of children was: decreased small airway function > mild obstructive lesions > normal pulmonary ventilation function > mixed ventilation dysfunction > mild restrictive lesions = mild restrictive lesions combined with decreased small airway function. Statistical tests on baseline data showed that there were no statistically significant differences in gender, age, height, weight, disease course and pulmonary ventilation function distribution between the two groups of children (all P>0.05), indicating that the case observations of the two groups of children were comparable.

[0214] 2 Comparison of clinical syndrome scores before and after treatment

[0215] 2.1 Comparison of main symptom scores between the two groups before and after treatment

[0216] Before treatment, the scores of five main symptoms, including nasal itching, sneezing, runny nose, nasal congestion and epistaxis, were compared between the two groups. There was no significant difference in the scores of the main symptoms between the two groups (all P>0.05).

[0217] After treatment, the single symptom scores of each main symptom in the two groups were significantly improved compared with those before treatment, and the difference was statistically significant (all P < 0.05); after treatment, the single symptom scores of each main symptom in the treatment group were lower than those in the control group (all P < 0.05), indicating that the treatment group was better than the control group in terms of improvement of the main symptoms, and the difference was statistically significant, as shown in Tables 13 and 14.

[0218] Table 13 The main symptom scores of the two groups of children before and after treatment and the comparison within the group

[0219]

[0220]

[0221] Table 14 Comparison of the main symptom scores of the two groups of children before and after treatment

[0222]

[0223] 2.2 Comparison of symptom scores between the two groups before and after treatment

[0224] Before treatment, the scores of five complications, including itchy eyes, itchy throat, dry mouth, fever, headache and nasal signs, were compared between the two groups. There was no significant difference in the scores of each comorbidity between the two groups (all P>0.05).

[0225] After treatment, the control group had a significant improvement in headache and nasal signs and symptoms compared with before treatment (all P < 0.05), and there was no statistically significant difference in the improvement of the symptom scores of itchy eyes, itchy throat, dry mouth and irritability and fever (all P > 0.05); after treatment, the treatment group had a significant improvement in itchy eyes, itchy throat, headache and nasal signs and symptoms compared with before treatment (all P < 0.05), and there was no statistically significant difference in the improvement of the symptom scores of dry mouth and irritability and fever (P > 0.05). After treatment, the comparison between the treatment group and the control group showed that the treatment group was better than the control group in the improvement of itchy eyes, itchy throat, and nasal signs and symptoms (all P < 0.05), and there was no statistically significant difference in the improvement of the symptom scores of dry mouth, irritability and fever, and headache (all P > 0.05), see Tables 15 and 16.

[0226] Table 15 Comparison of the scores of various complications before and after treatment in the two groups of children and within the group

[0227]

[0228] Table 16 Comparison of the scores of various complications in the two groups of children before and after treatment

[0229]

[0230] 2.3 Comparison of total clinical symptom scores between the two groups before and after treatment

[0231] Before treatment, the total scores of main symptoms, concomitant symptoms and syndromes were compared and analyzed between the two groups. There was no significant difference between the two groups (all P>0.05), which was clinically comparable.

[0232] After treatment, the total scores of main symptoms, concomitant symptoms and syndromes of the two groups of children were significantly reduced compared with those before treatment (all P < 0.001); among them, the improvement of the total scores of main symptoms, concomitant symptoms and syndromes in the treatment group was significantly better than that in the control group (all P < 0.001), see Tables 17 and 18.

[0233] Table 17 Clinical symptom scores of the two groups of children before and after treatment and intra-group comparison

[0234]

[0235] Table 18 Comparison of clinical syndrome scores between the two groups of children before and after treatment

[0236]

[0237] 2.4 Comparison of the effective rate of TCM syndromes between the two groups of children

[0238] After treatment, the total effective rate of the control group was 79.55%, including 5 cases of marked effect, 30 cases of effective, and 9 cases of ineffectiveness; the total effective rate of the treatment group was 95.56%, including 16 cases of marked effect, 27 cases of effective, and 2 cases of ineffectiveness. The difference in the total effective rate between the two groups of children was statistically significant (P < 0.05), see Table 19.

[0239] Table 19 Comparison of the total effective rate of TCM syndromes in the two groups of children after treatment

[0240]

[0241] 2.5 Comparison of peripheral blood EOS counts between the two groups before and after treatment

[0242] Before treatment, there was no significant difference in the peripheral blood EOS counts between the two groups (P>0.05), which was clinically comparable. After treatment, the peripheral blood EOS counts of the two groups were significantly reduced compared with those before treatment (all P<0.001), among which the improvement effect of the treatment group on the peripheral blood EOS counts was better than that of the control group (P<0.05), as shown in Table 20, Figure 1 .

[0243] Table 20 Comparison of peripheral blood EOS counts between the two groups before and after treatment (×10 9 / L, )

[0244]

[0245] Note: Compared with before treatment, △ P<0.05, △△ P<0.001; compared with the control group, * P<0.05, ** P<0.001.

[0246] III. Conclusion

[0247] The research results of the present invention show that Chinese medicine intervention has a good clinical effect on children's allergic rhinitis, can reduce the EOS count in the peripheral blood of children, relieve the clinical symptoms of children, improve the quality of life of children, and has good safety.

[0248] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for treating allergic rhinitis and adenoids hypertrophy in children, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 7-11 parts of honeysuckle, 7-11 parts of fritillaria thunbergii, 7-11 parts of forsythia suspensa, 13-17 parts of oyster, 7-11 parts of burdock fruit, 4-8 parts of magnolia, 4-8 parts of mint, 7-11 parts of atractylodes, and 7-11 parts of astragalus.

2. The Chinese medicine composition according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-10 parts of honeysuckle, 8-10 parts of fritillaria thunbergii, 8-10 parts of forsythia suspensa, 14-16 parts of oyster, 8-10 parts of burdock fruit, 5-7 parts of magnolia, 5-7 parts of mint, 8-10 parts of atractylodes, and 8-10 parts of astragalus.

3. The Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 9 parts of honeysuckle, 9 parts of fritillaria thunbergii, 9 parts of forsythia suspensa, 15 parts of oyster, 9 parts of burdock fruit, 6 parts of magnolia, 6 parts of mint, 9 parts of atractylodes, and 9 parts of astragalus.

4. The Chinese medicine composition according to any one of claims 1 to 3, characterized in that: The medicine of the Chinese medicine composition is tablet, capsule, granule, oral liquid or syrup.

5. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of medicines for treating allergic rhinitis and adenoids hypertrophy in children.

Citation Information

Patent Citations

  • Traditional Chinese medicine for treating rhinitis snuffles

    CN100998679A

  • Preparation method of compound traditional Chinese medicine nasal spray

    CN104042994A

  • Traditional Chinese medicine combination for curing chronic rhinitis

    CN104306673A

  • Traditional Chinese medicinal composition for treating child allergic rhinitis, and preparation method and application thereof

    CN104398711A